Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.
Inclisiran can achieve substantial and consistent reductions in LDL levels. In phase 3 trials, inclisiran showed a reduction in LDL cholesterol levels of up to 52% at month 17, with a good safety ...
Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...